Targeting of functional antibody-CD59 fusion proteins to a cell surface
Open Access
- 1 January 1999
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 103 (1) , 55-61
- https://doi.org/10.1172/jci4607
Abstract
Complement is involved in the pathogenesis of many diseases, and there is great interest in developing inhibitors of complement for therapeutic application. CD59 is a natural membrane-bound inhibitor of the cytolytic complement membrane attack complex (MAC). In this study, the preparation and characterization of antibody-CD59 (IgG-CD59) chimeric fusion proteins are described. Constructs were composed of soluble CD59 fused to an antibody-combining site at the end of CH1, after the hinge (H), and after CH3 Ig regions. The antigen specificity of each construct was for the hapten 5-dimethylamino-naphthalene-1-sulfonyl (dansyl). Correct folding of each IgG-CD59 fusion partner was indicated by recognition with anti-CD59 antibodies specific for conformational determinants and by IgG-CD59 binding to dansyl. The IgG-CD59 fusion proteins all bound specifically to dansyl-labeled Chinese hamster ovary cells and provided targeted cells, but not untargeted cells, with effective protection from complement-mediated lysis. Data indicate that CD59 must be positioned in close proximity to the site of MAC formation for effective function, and that modes of membrane attachment other than glycophosphatidylinositol linkage can affect CD59 functional activity.Keywords
This publication has 64 references indexed in Scilit:
- THE ROLE OF COMPLEMENT AND COMPLEMENT RECEPTORS IN INDUCTION AND REGULATION OF IMMUNITYAnnual Review of Immunology, 1998
- Complement in human diseaseImmunology Today, 1997
- TRANSGENIC PIGS EXPRESSING HUMAN CD59 AND DECAY-ACCELERATING FACTOR PRODUCE AN INTRINSIC BARRIER TO COMPLEMENT-MEDIATED DAMAGE1Transplantation, 1997
- Transfected CD59 protects mesangial cells from injury induced by antibody and complementKidney International, 1996
- Complement regulatory molecules: application to therapy and transplantationImmunology Today, 1995
- REGULATION OF THE COMPLEMENT CASCADE BY SOLUBLE COMPLEMENT RECEPTOR TYPE 1Transplantation, 1995
- IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODELTransplantation, 1991
- Soluble Human Complement Receptor Type 1: In Vivo Inhibitor of Complement Suppressing Post-Ischemic Myocardial Inflammation and NecrosisScience, 1990
- 20 KDa homologous restriction factor of complement resembles T cell activating proteinBiochemical and Biophysical Research Communications, 1989
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970